The stock of Bionano Genomics Inc (BNGO) has seen a 16.79% increase in the past week, with a -9.73% drop in the past month, and a -43.72% decrease in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.22% for BNGO. The simple moving average for the last 20 days is 2.04% for BNGO’s stock, with a simple moving average of -61.91% for the last 200 days.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
The 36-month beta value for BNGO is at 2.28. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNGO is 101.34M, and currently, shorts hold a 11.95% of that float. The average trading volume for BNGO on December 02, 2024 was 2.40M shares.
BNGO) stock’s latest price update
Bionano Genomics Inc (NASDAQ: BNGO)’s stock price has soared by 2.35 in relation to previous closing price of 0.26. Nevertheless, the company has seen a gain of 16.79% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-13 that Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes – IR Erik Holmlin – CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam – Scotiabank Destiny Hance – Ladenburg Thalmann Mark Massaro – BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today’s conference is being recorded.
Analysts’ Opinion of BNGO
Scotiabank gave a rating of “Sector Outperform” to BNGO, setting the target price at $4 in the report published on January 05th of the previous year.
BNGO Trading at -19.31% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.48% of loss for the given period.
Volatility was left at 10.22%, however, over the last 30 days, the volatility rate increased by 10.49%, as shares sank -7.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.86% lower at present.
During the last 5 trading sessions, BNGO rose by +16.12%, which changed the moving average for the period of 200-days by -79.52% in comparison to the 20-day moving average, which settled at $0.2563. In addition, Bionano Genomics Inc saw -86.16% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -3.24 for the present operating margin
- -0.02 for the gross margin
The net margin for Bionano Genomics Inc stands at -4.07. The total capital return value is set at -1.99. Equity return is now at value -161.77, with -100.85 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -6.47. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -21.24.
Currently, EBITDA for the company is -213.6 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.21. The receivables turnover for the company is 6.27for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
In conclusion, Bionano Genomics Inc (BNGO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
